explore -WSS

explore

author：leisure time 2025-10-03 00:04:05 - browse：87711

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： CDC Director Mandy Cohen on transparency, trust, and health

hotspot

WSS

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

In the gardens at Boston Children's Hospital, families find sanctuary

New Alzheimer's drugs heat up race for early detection blood tests

Cytokinetics CEO stresses company can launch heart drug on its own

When prostate cancer spreads, where it goes matters

Anxious about a speech? A startup wants you to pop a minty cardiac drug

leisure time

explore

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Readers respond to H5N1 and livestock movements, and more

Walensky prepares to leave CDC — and Congress — behind

The battle over 'scope creep' and who gets to be called 'doctor'

Moonlake's readout produced a cash windfall. Risks remain

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

The high cost of giving birth even with insurance

HIV vaccine remains elusive. Immunologists keep trying new ideas

Bright Health sells Medicare Advantage business to Molina

Former reverend arrested for allegedly killing 8

explore

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

Biogen says it will cut costs by $700 million, slash 1,000 jobs

What causes rare myocarditis in young men after Covid vaccines?

Helping hospitals and community health centers plan for resilience

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

focus

hotspot

hotspot

knowledge